Mahesh Karande, Omega Therapeutics CEO
September 26, 2023 07:00 AM EDTUpdated 08:18 AM
R&D

Omega Ther­a­peu­tic­s' epige­nom­ic med­i­cines re­duce MYC ex­pres­sion by 55% in ear­ly study of can­cer pa­tients

Ryan Cross

Senior Science Correspondent

Omega Ther­a­peu­tics, a com­pa­ny de­sign­ing ge­net­ic med­i­cines that di­al the out­put of genes up or down, on Tues­day morn­ing re­vealed the first da­ta from a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times